Список литературы

Bates D.W., Cullen D.J., Laird N. et al. Incidence of adverse drug events and potential adverse drug events. Implications for prevention // JAMA. 1995.Vol.274. P.29-34. Ernst F.R., Grizzle A.J.

Drug-related morbidity and mortality: updating the cost-of-illness model // J. Am. Pharm. Assoc. 2001.Vol.41. P.192-199. Johnson J.A., Bootman J.L. Dr, ug-related morbidity and mortality. A cost-of-illness model // Arch. Intern. Med. 1995. Vol.155. P.1949-1956. Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. Clin Oncol 2005;23:7811—7819. Ferrans VJ. Overview of cardiac pathology in relation to anthracycline cardiac toxicity // Cancer Treat. Rep. 1978. Vol. 62. P. 955–961. Urbanova D., Urban l., Carter A. et al. Cardiac troponins – biochemical markers of cardiac toxicity after cytostatic therapy // Neoplasma. 2006. Vol. 53, № 3. P. 183–190. Lewis W., Kleinerman J., Puszkin S. Interaction of adriamycin in vitro with cardiac myofibril proteins // Canc. Res. 1982. Vol. 50. P. 547–553. Berthiaume J.M., Oliveira P.J., Fariss M.W., Wallace K.B. Dietary vitamin E decreases doxorubicin-induced oxidative stress without preventing mitochondrial dysfunction // Cardiovasc. Toxicol. 2005. Vol. 5, № 3. P. 257–267. Chaiswing l., Cole M.P., St Clair D.K. et al. Oxidative damage precedes nitrative damage in adriamycin-induced cardiac mitochondrial injury // Toxicol. Pathol. 2004. Vol. 32, № 5. P. 536–547. Singal P.K., Iliskovic N. Doxorubicin-induced Cardiomyopathy // N. Engl. J. med. 1998. Vol. 339. P. 900–905. Schimmel K.J., Richel D.J., van den Brink R.B., Guchealaar H.J. Cardiotoxicity of cytotoxic drugs // Cancer Treat.

Rev. 2004. Vol. 30, № 2. P. 181–191. Shan K., Lincoff A.M., Young J.B. Anthracycline-induced cardiotoxicity // Ann. Intern. med. 1996. Vol. 125, № 1. P. 47–58. Olson R.D., Mushlin P.S., Breuner D.E. et al. Doxorubicin cardiotoxicity may be due to its metabolite, doxorubicinol // Proc. Natl. Acad. Sci. USA. 1988. Vol. 85. P. 3585–3589. Sacco G., Giampietro R., Salvatorelli E. et al. Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity // Br. J. Pharmacol. 2003., Vol. 139, № 3. P. 641–651. Berthiaume J.M., Wallace K.B. Adriamycin-induced oxidative mitochondrial cardiotoxicity // Cell Biol. Toxicol. 2007. Vol. 23, № 1. P. 15–25. Horenstein M.S., Vander Heide R.S., l’Ecuyer T.J. molecular basis of anthracycline-induced cardiotoxicity and its prevention // Mol. Genet. metab. 2000 Vol. 71, № 1–2. Р. 436–444. Licata S., Saponiero A., Mordente A., Minotti G. Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction // Chem. Res. Toxicol. 2000. Vol. 13, № 5. P. 414–420. Toko H., Oka T., Zou Y. et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy // Hypertens. Res. 2002. Vol. 25, № 4. P. 597–603. Yeh E.T., Tong A.T., lenihan D.J. et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management // Circulation. 2004. Vol. 109, № 25. P. 3122–3131. Von Hoff D.D., Layard M.W., Basa P. et al. Risk factors for doxorubicin-induced congestive heart failure // Ann. Intern. Med. 1979. Vol.91(5). P.710-717.

20а. Braverman AC, Antin JH, Plappert MT, Cook EF, Lee RT: Cyclophoshamide cardiotoxicity in bone marrow transplantation.: a prospective evaluation of new dosing regimens. J Clin Oncol 1991. №10. Р.995-1000. Doroshow J.H. Doxorubicin-induced cardiac toxicity // N.

Engl. J. Med. 1991. Vol. 324. P.843-845. Gianni L., Herman E.H., Lipshultz S.E. et al. Anthracycline Cardiotoxicity: From Bench to Bedside // J. Clin. Oncol. 2008. Vol.26 (22). P.3777-3784. Balbi G., Visconti S., Monteverde A. et al. Liposomal doxorubicin: a phase II trial // Acta Biomed. 2007. Vol.78. P.210-213. Ewer M.S., Martin F.J., Henderson C. et al. Cardiac safety of liposomal anthracyclines // Semin. Oncol. 2004. Vol. 31, № 6, Suppl. 13. P. 161–181. Swain S.M. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy // J. Clin. Oncol. 1997. Vol.15. P.1333-1340. Van Dalen E., Caron H., Dickinson H., Kremer L. Cardioprotective interventions for cancer patients receiving anthracyclines // Cochrane Database Syst. Rev. 2008. Vol. 2. CD003917. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer N Engl J Med 2005 Oct 20;353(16):1659-72. Ewer MS, Vooletich MT, Durand JB, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment J Clin Oncol 2005;23:7820—2826. Dow E, Schulman H, Agura E: Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 1993, 12:169-172. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J: Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981 , 141:758-763. Meinardi MT, Gietema JA, van der Graaf WT, van Veldhuisen DJ, Runne MA, Sluiter WJ, de Vries EG, Willemse PB, Mulder NH, van den Berg MP, Koops HS, Sleijfer DT: Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.
J Clin Oncol 2000, 18:1725-1732. Altena R, de Haas EC, Nuver J, et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. Br J Cancer 2009; 100(12):1861-1866. Lestuzzi C, Viei E, Picano E, Meneguzzi N: Coronary vasospasm as a cause of effort-related myocardial ischemia during low dose chronic continuous infusion of 5-fluorouracil. Am J Med 2001, 111:316-318. Frickhofen N, Beck FJ, Jung B, Fuhr HG, Andrasch H, Sigmund M: Capecitabine can induce acute coronary syndrome similar to 5-fluorouracil. Ann Oncol 2002 , 13:797-801. Sevelda P, Mayerhofer K, Obermair A, Stolzlechner J, Kurz C: Thrombosis with paclitaxel. Lancet 1994, 343:727-731. Kammula US, White DE, Rosenberg SA. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer. Cancer 1998, 83:797-805.

<< | >>

↑

Источник: М.Б. Стенина. МАТЕРИАЛЫ КОНГРЕССА. 2010

Еще по теме Список литературы:

- Детская онкология - Кардиоонкология - Лечение онкологических заболеваний - Онкогастроэнтерология - Онконефрология - Паллиативная медицина -

- Акушерство и гинекология - Анатомия - Андрология - Биология - Болезни уха, горла и носа - Валеология - Ветеринария - Внутренние болезни - Военно-полевая медицина - Восстановительная медицина - Гастроэнтерология и гепатология - Гематология - Геронтология, гериатрия - Гигиена и санэпидконтроль - Дерматология - Диетология - Здравоохранение - Иммунология и аллергология - Интенсивная терапия, анестезиология и реанимация - Инфекционные заболевания - Информационные технологии в медицине - История медицины - Кардиология - Клинические методы диагностики - Кожные и венерические болезни - Комплементарная медицина - Лучевая диагностика, лучевая терапия - Маммология - Медицина катастроф - Медицинская паразитология - Медицинская этика - Медицинские приборы - Медицинское право - Наследственные болезни - Неврология и нейрохирургия - Нефрология - Онкология - Организация системы здравоохранения - Оториноларингология - Офтальмология - Патофизиология - Педиатрия - Приборы медицинского назначения - Психиатрия - Психология - Пульмонология - Стоматология - Судебная медицина - Токсикология - Травматология - Фармакология и фармацевтика - Физиология - Фтизиатрия - Хирургия - Эмбриология и гистология - Эпидемиология -